Hormonal
Exercise induces the release of myokines (irisin, IL-6, IL-15, METRNL, BAIBA) and hepatokines (FGF21, ANGPTL4, follistatin) which mediate fat mass loss by promoting white adipose tissue (WAT) browning, increasing fatty acid oxidation, and reducing systemic inflammation.
To lose fat, focus on consistent exercise (aerobic or resistance) to trigger the release of 'exercise-inducible factors' like irisin and IL-6. These molecules help turn white fat into metabolically active brown/beige fat and improve insulin sensitivity, leading to sustained fat loss even after your workout ends. Don't just rely on the calories burned during the exercise; the hormonal changes are key.
Myokines such as irisin, interleukin-6 (IL-6), interleukin-15 (IL-15), meteorin-like (METRNL), and β-aminoisobutyric acid (BAIBA) have been consistently shown to be released by SkM in response to exercise. These exert beneficial physiologic and metabolic effects not only in SkM itself but also in distant tissues such as white adipose tissue (WAT)... to drive a systemic anti-inflammatory and insulin-sensitive state, permissive for optimization of total-body energy expenditure.
Why this rating
The paper is a narrative review summarizing various preclinical and clinical studies; it does not present new primary data.
Source
The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review
Adrian M. González-Gil et al. · Nutrients · 2020
DOI 10.3390/nu12061899
More from this paper
- High baseline levels of the hepatokine Selenoprotein P (SeP) are associated with 'exercise resistance,' blunting the beneficial metabolic adaptations to exercise and reducing aerobic capacity in obese individuals.Moderate
- Exercise reduces levels of detrimental hepatokines like Fetuin A and Selenoprotein P, which contributes to decreased visceral adipose tissue (VAT) mass and improved insulin sensitivity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →